AICAR: what the research shows
- By Reed Calder
- Last reviewed Nov 16, 2026
- 42 studies and official documents checked
In short
AICAR (acadesine, AICA riboside) is a small molecule, not a peptide: a nucleoside, a ring-shaped base joined to a sugar, that resembles adenosine. Cells take it up and turn it into ZMP, an AMP look-alike that switches on AMPK, a cell energy sensor, though AICAR also acts in ways that don’t need AMPK.
In sedentary mice, 4 weeks of injected AICAR made them run about 44% farther on a treadmill. In people, the studies gave it into a vein or artery and measured other things. In 29 healthy men it raised muscle glucose uptake 2.1-fold, against 4.7-fold for cycling, with no measured AMPK activation. In 10 healthy people in another study it had no effect on glucose uptake but raised heart rate and lowered blood pressure. Its main human use was heart surgery: a 1997 pooled analysis of 4,043 patients found 27% fewer heart attacks, but RED-CABG was stopped for futility after 3,080 of a planned 7,500 patients, with the main outcome in 5.1% on acadesine and 5.0% on placebo.
Both cancer trials we found reported kidney problems, and one was stopped early at its highest dose. We found no human trial of AICAR for fitness, fat loss or taken by mouth, and in the first study in healthy men less than 5% was absorbed from an oral solution. There is no FDA application or drug listing for it, and the 2026 WADA list prohibits AMPK activators, AICAR among them, at all times.
EvidenceCellAnimalHumanmouse running tests; infusion studies in people; heart-surgery and leukemia trials; no human fitness trial
You’ll often read that AICAR is an “exercise in a pill” that burns fat, improves insulin sensitivity, works by mouth and is safe because the body makes it. This page covers what AICAR is, what was studied in mice and in people, the usual claims checked, what the studies used, side effects, where it stands with the FDA and in sport, and what’s still unknown.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| AICAR, AICAr, acadesine, AICA riboside | The nucleoside: a ring-shaped base joined to a sugar. Acadesine is its drug name, and Acadra was the brand name used in an MDS/AML trial (PubChem CID 17513; Cluzeau et al., 2019) | Yes: infusions into a vein or artery |
| ZMP, AICA ribotide, AICA ribonucleotide | The phosphorylated form inside cells, and a normal step in making purines. Some papers also call this one AICAR (PubChem CID 65110; Višnjić et al., 2021) | Measured in red blood cells after AICAR infusions (Bosselaar et al., 2011) |
| “AICAR peptide” | A search phrase and product label. AICAR is a nucleoside with the formula C9H14N4O5, not a peptide (PubChem) | See the first row |
| Exercise mimetic, exercise in a pill | Nicknames that took off after a 2008 mouse paper (Narkar et al., 2008; Višnjić et al., 2021) | Not tested for fitness in people |
| MOTS-c and BAM15 | Different compounds named in the same WADA entry as AICAR. MOTS-c is a peptide; see MOTS-c. BAM15 is a small molecule; see BAM15 (WADA, 2026) | Covered separately |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The number below is for AICAR (acadesine) itself; ZMP has its own, CAS 3031-94-5 (PubChem).
| Form | CAS number | Registry record |
|---|---|---|
| AICAR (acadesine) | 2627-69-2 | FDA GSRS |
What AICAR is
AICAR is a nucleoside with the formula C9H14N4O5 and a weight of 258.23 g/mol (PubChem CID 17513). It resembles adenosine. Cells take it in through adenosine transporters, and an enzyme adds a phosphate to make ZMP (Višnjić et al., 2021). In 10 healthy people given AICAR, red blood cells rapidly took it up and made ZMP (Bosselaar et al., 2011).
ZMP is an AMP look-alike and activates AMPK, but about 40 to 50 times less potently than AMP, and it builds up in cells to high levels, so effects that don’t need AMPK were always likely (Višnjić et al., 2021). In liver cells AICA riboside cut oxygen use, and still did in mouse cells lacking both catalytic AMPK subunits, and ZMP blocked a respiratory enzyme complex in isolated rat mitochondria (Guigas et al., 2007). A 2021 review says AICAR is no longer recommended as a specific AMPK activator, mainly because far more selective ones now exist (Višnjić et al., 2021).
AMPK is a cell energy sensor switched on by exercise, low oxygen and low blood sugar. USADA says the effects of activating it are extremely complex because it works in so many pathways (USADA).
The body also makes ZMP as a normal step in building purines. WADA’s anti-doping lab project notes AICAR occurs naturally in healthy people’s urine at up to 7,500 ng/mL, and that levels above 3,500 ng/mg creatinine after illicit use were assumed to last only hours (WADA project page).
In people it was first studied as an adenosine-regulating agent for the heart: the first safety study, in 1991, was for ischemic heart disease, which is why the trials below use the name acadesine (Dixon et al., 1991; Višnjić et al., 2021).
What has been studied
Every human study below gave AICAR by infusion into a vein or an artery, except one comparison of an oral solution. Most of the mouse and rat work used injections.
In people: heart surgery
| Study | Who | What was used | What it found |
|---|---|---|---|
| Leung et al., 1994 | 116 patients having bypass surgery; randomized, double-blind | Placebo or a low or high dose of acadesine by vein for 7 hours | Safe on the study’s measures: uric acid rose only on the high dose (mean 1.6 mg/dL) without clinical problems. Signs of heart ischemia on ECG and ultrasound did not differ significantly between groups |
| McSPI, 1995 | 633 patients at 20 U.S. centers having bypass surgery | Placebo, 0.05 or 0.1 mg/kg per minute by vein for 7 hours, plus acadesine in the heart-stopping solution | Heart attack by the preset definition in 24%, 26% and 21% (p = 0.574); all cardiovascular outcomes 30%, 30% and 22% (p = 0.151). A stricter definition chosen afterward favored the high dose (p = 0.018 against a corrected cutoff of 0.017) |
| Menasché et al., 1995 | 821 patients having bypass surgery (418 placebo, 403 acadesine) | 0.1 mg/kg per minute by vein for 7 hours, plus the heart-stopping solution | Heart attacks overall did not change significantly. Q-wave heart attacks fell in the high-risk group, from 19.7% to 10.0% (p = 0.032). All adverse cardiovascular outcomes 19.4% vs 18.4%; deaths 3.4% vs 2.7%. No adverse events were related to acadesine |
| Mangano et al., 1997 | Pooled data on 4,043 patients from 5 randomized trials | Acadesine 0.1 mg/kg per minute for 7 hours and in the heart-stopping solution, or placebo | Heart attacks down 27% (odds ratio 0.69, 95% CI 0.51 to 0.95); cardiac death through day 4 down 50% (0.52, 0.27 to 0.98); stroke not significantly reduced (0.69, 0.44 to 1.08). Adverse events were similar except a brief rise in uric acid |
| Mangano et al., 2006 | 2,698 patients at 54 institutions | Placebo or acadesine, same regimen | A heart attack occurred in 100 patients (3.7%). Among those, 2-year mortality was 27.8% on placebo (15 of 54) and 6.5% on acadesine (3 of 46), p = 0.006. This is a subgroup, not the whole trial |
| Newman et al., 2012 (RED-CABG) | 3,080 of a planned 7,500 patients at 300 sites in 7 countries; median age 66 | Acadesine 0.1 mg/kg per minute for 7 hours, or placebo | Stopped for futility. Death, nonfatal stroke or need for mechanical support for severe left-ventricular dysfunction by day 28 in 75 of 1,493 on placebo (5.0%) and 76 of 1,493 on acadesine (5.1%), odds ratio 1.01 (0.73 to 1.41). No difference in the key secondary outcomes |
| Holdright et al., 1994 | 12 patients with stable angina; randomized, double-blind, five-way | Four doses of acadesine (6 to 48 mg/kg) or placebo by vein during an exercise test | Time to ST depression changed by -0.1%, 11.1%, 12.9% and -3.2% against placebo, not significant. Angina time and total exercise time were not consistently changed |
EvidenceCellAnimalHumanrandomized trials; the pooled analysis and a subgroup went one way, the largest trial the other
In people: muscle glucose, blood sugar and fat
| Study | Who | What was used | What it found |
|---|---|---|---|
| Cuthbertson et al., 2007 | 29 healthy men | AICAR infused for 3 hours, compared with bicycle exercise | Muscle glucose uptake rose 2.1-fold on AICAR and 4.7-fold with cycling. Muscle AMPK activity and phosphorylation did not change; ERK1/2 phosphorylation did. Whole-body glucose disposal rose 7%, from 9.3 to 10 mg/kg per minute |
| Babraj et al., 2009 | 6 young men, 8 older men and 8 men with type 2 diabetes (the young group had been published before) | AICAR infused at 10 or 20 mg/kg per hour, from hour 3 to 6 of a tracer infusion | At 10 mg/kg per hour, uptake rose 2.9-fold in young men, 1.8-fold in older men and 1.6-fold in men with diabetes. AMPK activity and phosphorylation were unchanged. Age, not diabetes, blunted the response |
| Bosselaar et al., 2011 | 10 healthy people (8 with paired data) | AICAR 67 mg/kg over the last 60 minutes of an insulin clamp, or saline | No difference in whole-body glucose infusion or forearm glucose uptake. Heart rate rose more (58 to 70 beats a minute against 60 to 63 on placebo) and blood pressure fell; the authors suspect widened blood vessels |
| Bosselaar et al., 2009 | 24 healthy people | AICA riboside into the forearm artery at four doses | Forearm blood flow rose from 2.0 to 13.2 mL per minute per dL through nitric oxide. Forearm glucose uptake did not change despite high blood levels |
| Boon et al., 2008 | 10 men with type 2 diabetes, mean age 64 | AICAR 0.75 mg/kg per minute by vein, or saline | The liver released less glucose and blood glucose fell more (p < 0.001). Fatty-acid appearance and disappearance both fell, with a lower fatty-acid level. Muscle AMPK phosphorylation was not increased |
EvidenceCellAnimalHumansmall acute studies of hours, not treatments
In people: cancer trials
| Study | Who | What was used | What it found |
|---|---|---|---|
| Van Den Neste et al., 2013 (NCT00559624) | 24 patients with relapsed or refractory chronic lymphocytic leukemia; open-label, no comparison group | Acadesine over 4 hours by vein: single doses of 50 to 315 mg/kg in 18 patients, then 210 mg/kg twice in 3 and five times in 3 | A dose of 210 mg/kg was the maximum tolerated. Raised uric acid was common and controlled with allopurinol. Other events: brief anemia or low platelets, kidney impairment, and brief infusion-related low blood pressure that was clinically significant. Some patients had fewer circulating leukemia cells and smaller lymph nodes, but results varied. The trial did not prospectively assess formal remission |
| Cluzeau et al., 2019 (NCT01813838) | Patients with myelodysplastic syndrome or acute myeloid leukemia that no longer responded to azacitidine | Acadesine, highest dose 210 mg/kg | The trial was stopped because the highest dose caused serious kidney side effects in several patients. The abstract reports one very good response among 4 patients (it says the trial was set up for 12); the registry lists 5 enrolled and is marked terminated for renal toxicity |
EvidenceCellAnimalHumantwo small uncontrolled trials; neither shows a treatment benefit
In people: what the body does with it
| Study | Who | What was used | What it found |
|---|---|---|---|
| Dixon et al., 1991 | Healthy men; four on drug and two on placebo at each dose, a week between routes | 10, 25, 50 and 100 mg/kg by mouth in solution and by vein | Well tolerated, with only mild, brief side effects in both drug and placebo recipients. By vein the drug left plasma in two phases with a final half-life of 1.4 hours; 8% appeared in urine unchanged. Taken by mouth in solution it was poorly absorbed: under 5% |
| Dixon et al., 1993 | 4 healthy men | 25 mg/kg of radiolabeled acadesine over 15 minutes by vein | Intact acadesine was measurable for only 2 hours, while total radioactivity declined with a final half-life of about 1 week. Uric acid was the main metabolite. The phosphorylated form sat in red cells, 30% of blood radioactivity at the end of the infusion. Over 2 weeks 44% of the dose was in urine and 4% in feces, 5% of it as intact drug |
EvidenceCellAnimalHumanfour healthy men in the first study of each kind
In animals and cells: muscle and exercise
| Study | Model | What was used | What it found |
|---|---|---|---|
| Narkar et al., 2008 | Sedentary 8-week-old C57BL/6J mice, 15 to 20 per group in the treadmill test | AICAR 500 mg/kg a day, injected into the abdominal cavity, for 4 weeks | Mice ran about 23% longer and 44% farther than vehicle mice. The paper calls AICAR orally active, but its methods give it by injection; only a second drug was given by mouth. A 2008 erratum corrects a different figure (1C, muscle staining images); the authors say the treadmill data are unaffected |
| Wilcox et al., 2025 | Old mice (23 months) | AICAR 300 to 500 mg/kg a day under the skin for 31 days | Treadmill capacity fell 24.5% in saline-treated old mice and not in AICAR-treated ones. Muscle force was 26.4% higher and quadriceps weight about 8% higher; cytochrome C rose about 33% and citrate synthase about 22% |
| Brockhoff et al., 2017 | Mouse model of myotonic dystrophy type 1 | AICAR | A strong reduction of myotonia, with partial correction of mis-spliced genes |
| Cerveró et al., 2016 | Mouse model of severe spinal muscular atrophy | AICAR, chronic | Muscle atrophy and nerve-muscle junction changes improved, but there was no improvement in survival or motor performance and no relief of motor-neuron loss |
| Bolster et al., 2002 | Male rats | AICAR injections | Muscle protein synthesis fell to 45% of the control value, with lower mTOR pathway activity |
EvidenceCellAnimalHumaninjections in mice and rats; no human fitness trial
In animals and cells: blood sugar, fat, bone and reproduction
| Study | Model | What was used | What it found |
|---|---|---|---|
| Halseth et al., 2002 | Diabetic ob/ob and db/db mice | AICAR under the skin, once or twice a day for 8 days | Morning blood glucose fell about 30 to 35% by day 8, but serum triglycerides rose about 2.5- to 3-fold |
| Blanco et al., 2018 | 11 premature baboons | AICAR by vein for 5 days (5 animals) or placebo (6) | Insulin-stimulated glucose disposal did not improve (12.8 on placebo and 12.4 on AICAR, in mg/kg per minute, p = 0.8). One animal developed complications; the authors say AICAR may have adverse effects |
| Quinn et al., 2010 | Mice and bone cells | AICA riboside | A 49.5% loss of trabecular bone volume and more osteoclasts. AICA riboside also stimulated osteoclast differentiation in cells without AMPK activity, so the effect did not need AMPK |
| Calder et al., 2017 | Mouse embryos in culture | AICAR 0 to 2,000 µM for 48 hours from the 2-cell stage; 1,000 µM for 9 hours on blastocysts | Fewer embryos reached the blastocyst stage and cell numbers fell. In blastocysts it caused collapse and leakier tight junctions, with unaffected, reversible and irreversible embryos. The authors say some effects may not involve AMPK |
| Bowdridge et al., 2017 | Granulosa cells from 26 IVF patients, in a dish (the patients were not given the drug) | AICAR on cells | AICAR lowered progesterone production (p < 0.001) |
| Piccolo et al., 2025 | Human retinal organoids (cells grown from stem cells) | AICAR and a second compound | They did not help a mutant retinal protein fold and travel, and instead lowered its RNA and protein, which does not support the earlier cell-culture finding that they could correct it |
EvidenceCellAnimalHumanmostly mice and cells; not shown in people
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| AICAR works like exercise in a pill | Untested | We found no study of AICAR for fitness in people. In 29 healthy men the infusion raised muscle glucose uptake 2.1-fold against 4.7-fold for cycling, without AMPK activation (Cuthbertson et al., 2007). The mouse results used injections (Narkar et al., 2008) |
| It increases endurance | Untested | Sedentary mice ran about 44% farther after 4 weeks of injections, and old mice kept their running capacity (Narkar et al., 2008; Wilcox et al., 2025). We found no human endurance study |
| It burns fat | Untested | We found no human fat-loss study. In 10 men with type 2 diabetes an infusion lowered fatty-acid turnover and the fatty-acid level (Boon et al., 2008). In diabetic mice triglycerides rose 2.5- to 3-fold (Halseth et al., 2002) |
| It lowers blood sugar and improves insulin sensitivity | Mixed | It lowered blood glucose in men with type 2 diabetes by cutting liver output, and in diabetic mice by 30 to 35%. It did not improve glucose uptake in healthy people on insulin or insulin-stimulated disposal in baboons (Boon et al., 2008; Halseth et al., 2002; Bosselaar et al., 2011; Blanco et al., 2018) |
| It builds muscle | Untested | We found no human study of muscle growth. In old mice 31 days of AICAR left muscle force 26.4% higher, while in rats it cut muscle protein synthesis to 45% of control (Wilcox et al., 2025; Bolster et al., 2002) |
| It protects the heart | Mixed | A pooled analysis of 4,043 surgery patients found 27% fewer heart attacks, but the 633- and 821-patient trials missed their main goal and RED-CABG, with 3,080 patients, was stopped for futility (Mangano et al., 1997; McSPI, 1995; Menasché et al., 1995; Newman et al., 2012) |
| It treats cancer | Mixed | Two small uncontrolled trials: fewer circulating cells in some leukemia patients, and a second trial stopped for serious kidney toxicity at its highest dose (Van Den Neste et al., 2013; Cluzeau et al., 2019) |
| It works when taken by mouth | Contradicted | In the first study in healthy men less than 5% was absorbed from an oral solution. The mouse running study injected it, although the paper calls it orally active (Dixon et al., 1991; Narkar et al., 2008) |
| It is a peptide | Contradicted | No. It is a nucleoside with the formula C9H14N4O5 (PubChem) |
| It is a clean AMPK switch | Mixed | It activates AMPK in cells and animals, but muscle AMPK activity or phosphorylation did not rise in three human infusion studies, and several effects need no AMPK (Cuthbertson et al., 2007; Babraj et al., 2009; Boon et al., 2008; Guigas et al., 2007; Višnjić et al., 2021) |
| It has no side effects because the body makes it | Contradicted | The infusion trials reported high uric acid, low blood pressure, kidney impairment and, at 210 mg/kg, serious kidney effects in several patients. In mice it caused bone loss and harmed embryos in culture (Van Den Neste et al., 2013; Cluzeau et al., 2019; Quinn et al., 2010; Calder et al., 2017) |
| It reverses muscle aging | Untested | Only in 23-month-old mice, where it kept treadmill capacity and raised muscle force. We found no human study (Wilcox et al., 2025) |
| AICAR is an FDA-approved drug | Contradicted | No. We found no Drugs@FDA application and no drug listing for acadesine or AICAR; the phase 3 heart-surgery trial was stopped for futility (openFDA; openFDA NDC; Newman et al., 2012) |
| Research-grade AICAR contains the amount on the label | Untested | We found one analysis of AICAR bought from internet suppliers, in 2010: it was authentic but the amount was considerably lower than the label. We found no analysis of products sold now (Thevis et al., 2011) |
| AICAR is banned in sport | Supported | Yes. The 2026 WADA list names AMPK activators including AICAR, prohibited at all times, and USADA says athletes cannot get an exemption for it (WADA, 2026; USADA) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | What was tested | Amount and route |
|---|---|---|
| Narkar et al., 2008 | Running endurance in mice | 500 mg/kg a day, injected into the abdominal cavity, for 4 weeks |
| Wilcox et al., 2025 | Old mice | 300 to 500 mg/kg a day under the skin for 31 days |
| Dixon et al., 1991 | Safety and absorption in healthy men | 10, 25, 50 and 100 mg/kg by mouth in solution and by vein, a week apart |
| Dixon et al., 1993 | Where it goes in the body | 25 mg/kg of radiolabeled drug over 15 minutes by vein |
| Holdright et al., 1994 | Exercise test in angina | 6, 12, 24 and 48 mg/kg by vein |
| Newman et al., 2012 and the other heart-surgery trials | Heart surgery | 0.1 mg/kg per minute by vein for 7 hours, plus acadesine in the heart-stopping solution (0.05 for the low dose in one trial) |
| Babraj et al., 2009 | Muscle glucose uptake | Infused at 10 or 20 mg/kg per hour, for 3 hours |
| Bosselaar et al., 2011 | Insulin clamp in healthy people | 67 mg/kg by vein over 60 minutes |
| Boon et al., 2008 | Type 2 diabetes | 0.75 mg/kg per minute by vein |
| Van Den Neste et al., 2013 | Leukemia | Single doses of 50 to 315 mg/kg over 4 hours by vein; 210 mg/kg was the maximum tolerated |
Every human amount above was given into a vein by trial staff with monitoring, except the oral solution in the 1991 study. The 210 mg/kg dose that was the maximum tolerated in the first leukemia trial caused serious kidney effects in several patients in the second. Nothing here is a dosing recommendation, and we don’t repeat schedules from seller pages.
Side effects and safety
- In the leukemia trials. In 24 patients, raised uric acid (grade 2 or higher) was common and controlled with allopurinol, and there were brief anemia or low platelets, kidney impairment and brief infusion-related low blood pressure that was clinically significant (Van Den Neste et al., 2013). A second trial was stopped because the highest dose, 210 mg/kg, caused serious kidney side effects in several patients; the registry lists it as terminated for renal toxicity with 5 enrolled (Cluzeau et al., 2019; NCT01813838).
- In heart-surgery trials. Adverse events were similar to placebo except a brief rise in uric acid (Mangano et al., 1997; Leung et al., 1994). In RED-CABG, serious events through day 28 occurred in 327 of 1,442 on acadesine and 329 of 1,457 on placebo (ClinicalTrials.gov results).
- Lactate and blood sugar. In 47 patients having coronary angiography, acadesine at 5 to 50 mg/kg by vein raised blood lactate by up to 60% against placebo (p < 0.001), which the authors read as a possible sign of increased anaerobic glycolysis (de Jonge et al., 1997). A 2021 review’s table of AICAR trials lists mild, symptom-free low blood sugar and raised uric acid in the 1994 angina trial (Višnjić et al., 2021). None of the human studies we read describes lactic acidosis.
- In healthy volunteers. Doses of 10 to 100 mg/kg were tolerated with mild, brief side effects in both drug and placebo recipients (Dixon et al., 1991). In the insulin-clamp study heart rate rose and blood pressure fell (Bosselaar et al., 2011), and into the forearm artery it widened vessels through nitric oxide (Bosselaar et al., 2009).
- In animals and cells. About 49.5% trabecular bone loss in mice (Quinn et al., 2010), fewer and leakier embryos in culture (Calder et al., 2017), triglycerides up 2.5- to 3-fold in diabetic mice (Halseth et al., 2002), and complications in one premature baboon (Blanco et al., 2018). These aren’t shown in people.
- What USADA says. It warns that too much AMPK activation, or activation in the wrong tissue, can cause serious side effects including neurodegeneration and stopped cell division, and that AICAR has not been extensively studied in people (USADA).
- Product quality. In 2010 the Cologne doping laboratory bought AICAR from internet suppliers as 100 mg portions; it was authentic but the amount was considerably lower than the label, and the parcels were marked “amino acids” and “green tea extract” (Thevis et al., 2011). We found no analysis of products sold now.
- Not known. Long-term safety, safety in pregnancy, interactions, and any effect of repeated dosing: the longest course we found in people was five doses in 3 leukemia patients. Side effects people report online aren’t covered here; they come from users, not studies.
Legal and approval status
- Not approved. We found no Drugs@FDA application and no drug listing for acadesine or AICAR (openFDA; openFDA NDC). USADA says it is not approved for use in humans anywhere and is not available as a medication (USADA).
- Compounding. AICAR and acadesine aren’t named in the FDA’s list of bulk substances nominated for compounding under section 503A, updated May 14, 2026, or on the FDA’s page of bulk substances that may present significant safety risks, current as of April 22, 2026 (FDA document; FDA page). We did not research whether pharmacies may lawfully compound it.
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides, not AICAR (Reuters, 2026).
- Other countries. We did not check how other countries regulate it.
- Sport. The World Anti-Doping Agency’s 2026 list, section S4.4.1, names AMP-activated protein kinase activators, including BAM15, AICAR and MOTS-c, prohibited at all times (WADA, 2026). USADA says athletes cannot get a therapeutic use exemption for it, because it is not approved anywhere (USADA).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and from the FDA:
- “Peptide.” AICAR is a nucleoside, not a peptide.
- “Orally active.” The famous mouse study injected it, and in the first human study under 5% was absorbed from an oral solution.
- “Exercise in a pill.” The evidence is in mice. In people the muscle response to an infusion was less than half that of cycling.
- “It activates AMPK.” True in cells and animals, but in human muscle infusions AMPK activity and phosphorylation didn’t rise, and some effects don’t need it.
- “Natural, so safe.” The body makes ZMP in tiny amounts. The doses in trials were milligrams per kilogram, and they caused kidney, blood pressure and uric acid effects.
- “Clinical trials.” Ask which: the phase 3 heart-surgery trial was stopped for futility, and the two cancer trials were small. None was for fitness.
- “Research grade, third-party tested.” The one analysis we found, from 2010, measured less than the label. Ask for the test report for the batch.
- Competition. The 2026 WADA list prohibits it at all times.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
Trials under way
We found no AICAR or acadesine trial that is recruiting or active, so there is nothing to list on our recruiting or in-progress pages. ClinicalTrials.gov lists 5 records that name it as an intervention (search, November 16, 2026), and all are finished or stopped: RED-CABG, terminated with 3,080 enrolled and results posted (NCT00872001); a leukemia phase 1 study, completed, with no results posted (NCT00559624); the MDS/AML study, terminated for renal toxicity with 5 enrolled (NCT01813838); a Lesch-Nyhan pilot, completed with 2 enrolled and no results posted (NCT00004314); and a study of exercise-triggered glucose uptake in type 2 diabetes with AICAR among its interventions, completed, with no results posted (NCT00168519). USADA’s page says AICAR is being evaluated in human clinical trials; we found none active.
What’s still unknown
- Whether AICAR does anything for fitness, fat loss or muscle in people; we found no trial.
- Whether any oral dose or oral form reaches effective levels in people; in the first human study less than 5% was absorbed.
- What repeated dosing does over weeks or months; all human exposure we found was infusions of hours, and the longest course was five doses in 3 patients.
- Whether the bone loss in mice and the embryo effects in culture occur in people.
- How much of AICAR’s effect needs AMPK, since human muscle infusions raised glucose uptake without measured AMPK activation.
- What is in AICAR sold online now; we found one analysis, from 2010.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention AICAR. We recheck every month. Last checked Nov 16, 2026.
Flagged studies that mention AICAR
| Study | What it was about | Status |
|---|---|---|
| Li et al., 2020 | MicroRNA-206 inhibition and activation of the AMPK/Nampt signalling pathway enhance sevoflurane post-conditioning-induced amelioration of myocardial ischaemia/reperfusion injury. | Retracted (2022) · notice |
| Yang et al., 2020 | Knockdown of HMGB1 Suppresses Hypoxia-Induced Mitochondrial Biogenesis in Pancreatic Cancer Cells. | Retracted (2026) · notice |
| Hu and Liu, 2016 | Resveratrol via activation of LKB1-AMPK signaling suppresses oxidative stress to prevent endothelial dysfunction in diabetic mice. | Retracted (2021) · notice |
| Yu et al., 2015 | Activation of AMPK improves lipopolysaccharide-induced dysfunction of the blood-brain barrier in mice. | Retracted (2018) · notice |
| Song et al., 2013 | Transcription factor Krüppel-like factor 2 plays a vital role in endothelial colony forming cells differentiation. | Retracted (2024) · notice |
| Liu et al., 2010 | Activation of AMP-activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins Bcl-2 and survivin. | Retracted (2020) · notice |
| Wang et al., 2009 | In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. | Retracted (2026) · notice |
| Xie et al., 2008 | Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. | Retracted (2023) · notice |
| Ropelle et al., 2008 | Central exercise action increases the AMPK and mTOR response to leptin. | Retracted (2018) · notice |
| An et al., 2007 | Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. | Retracted (2020) · notice |
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Dixon et al., 1991 | J Clin Pharmacol | No retraction or concern |
| Menasché et al., 1995 | J Thorac Cardiovasc Surg | No retraction or concern |
| PubMed 7574044 | Anesthesiology | No retraction or concern |
| Leung et al., 1994 | Anesth Analg | No retraction or concern |
| Holdright et al., 1994 | Cardiovasc Drugs Ther | No retraction or concern |
| Dixon et al., 1993 | J Clin Pharmacol | No retraction or concern |
| Mangano, 1997 | JAMA | No retraction or concern |
| de Jonge et al., 1997 | Eur J Pharmacol | No retraction or concern |
| Bolster et al., 2002 | J Biol Chem | No retraction or concern |
| Halseth et al., 2002 | Biochem Biophys Res Commun | No retraction or concern |
| Mangano et al., 2006 | J Am Coll Cardiol | No retraction or concern |
| Guigas et al., 2007 | Biochem J | No retraction or concern |
| Cuthbertson et al., 2007 | Diabetes | No retraction or concern |
| Narkar et al., 2008 | Cell | No retraction or concern |
| Boon et al., 2008 | Diabetologia | No retraction or concern |
| Babraj et al., 2009 | Am J Physiol Endocrinol Metab | No retraction or concern |
| Bosselaar et al., 2009 | Am J Physiol Endocrinol Metab | No retraction or concern |
| Quinn et al., 2010 | FASEB J | No retraction or concern |
| Bosselaar et al., 2011 | J Clin Pharmacol | No retraction or concern |
| Thevis et al., 2011 | Drug Test Anal | No retraction or concern |
| Newman et al., 2012 | JAMA | No retraction or concern |
| Van Den Neste et al., 2013 | Cancer Chemother Pharmacol | No retraction or concern |
| Cerveró et al., 2016 | Neurotherapeutics | No retraction or concern |
| Brockhoff et al., 2017 | J Clin Invest | No retraction or concern |
| Bowdridge et al., 2017 | Reprod Biol Endocrinol | No retraction or concern |
| Calder et al., 2017 | Mol Hum Reprod | No retraction or concern |
| Blanco et al., 2018 | PLoS One | No retraction or concern |
| Cluzeau et al., 2019 | Int J Mol Sci | No retraction or concern |
| Višnjić et al., 2021 | Cells | No retraction or concern |
| Wilcox et al., 2025 | FASEB Bioadv | No retraction or concern |
| Piccolo et al., 2025 | Invest Ophthalmol Vis Sci | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is AICAR?
AICAR is acadesine, a nucleoside that resembles adenosine. Cells convert it to ZMP, which activates the energy sensor AMPK, and it has effects that don’t need AMPK. It is a small molecule with the formula C9H14N4O5 (PubChem; Višnjić et al., 2021).
Is AICAR a peptide?
No. It is a nucleoside, a ring-shaped base joined to a sugar, with a weight of 258.23 g/mol, not a chain of amino acids (PubChem CID 17513).
What does AICAR do?
In mice, injections raised running endurance. In people, infusions raised muscle glucose uptake in some studies, lowered liver glucose output in men with type 2 diabetes, widened blood vessels and lowered blood pressure. Its main human use was heart surgery, where the largest trial was stopped for futility (Narkar et al., 2008; Cuthbertson et al., 2007; Boon et al., 2008; Bosselaar et al., 2011; Newman et al., 2012).
Does AICAR work like exercise?
Only partly, and only measured in muscle. In 29 healthy men an infusion raised muscle glucose uptake 2.1-fold against 4.7-fold for cycling, without AMPK activation. We found no human fitness trial (Cuthbertson et al., 2007).
Does AICAR burn fat?
We found no human fat-loss study. In 10 men with type 2 diabetes an infusion lowered fatty-acid turnover, and in diabetic mice triglycerides rose 2.5- to 3-fold (Boon et al., 2008; Halseth et al., 2002).
Does AICAR build muscle?
We found no human study. Old mice given AICAR for 31 days had 26.4% more muscle force, while in rats it cut muscle protein synthesis to 45% of control (Wilcox et al., 2025; Bolster et al., 2002).
Does AICAR give you energy?
We found no study that measured energy or fatigue in people given AICAR. AMPK is called a cell energy sensor, but that is cell biology, not a feeling. In mice it increased running distance (Narkar et al., 2008).
Does AICAR work orally?
We found no human study showing it does. In the first study in healthy men, under 5% was absorbed from an oral solution, and the mouse running study injected it even though the paper calls it orally active (Dixon et al., 1991; Narkar et al., 2008).
What are the side effects of AICAR?
In trials: high uric acid, low blood pressure during infusions, kidney impairment, and serious kidney side effects at 210 mg/kg in several patients in one trial. In mice: bone loss and, in embryos in culture, harm to development (Van Den Neste et al., 2013; Cluzeau et al., 2019; Quinn et al., 2010; Calder et al., 2017).
What dose of AICAR did the studies use?
It varied by study and was always given under supervision, mostly by vein: for example 0.1 mg/kg per minute for 7 hours in heart surgery and single doses of 50 to 315 mg/kg in leukemia. See what the studies used. It is not a dosing recommendation (Newman et al., 2012; Van Den Neste et al., 2013).
How long does AICAR stay in the body?
By vein, plasma levels fell with a half-life of 1.4 hours and intact drug was measurable for about 2 hours, but total radioactivity from a labeled dose fell with a half-life of about 1 week, mostly as metabolites such as uric acid (Dixon et al., 1991; Dixon et al., 1993).
Is AICAR FDA-approved?
No. We found no Drugs@FDA application and no drug listing for acadesine or AICAR (openFDA; openFDA NDC).
Why is AICAR banned?
The 2026 WADA list prohibits AMPK activators, including AICAR, at all times, and USADA says they are on the list for their potential performance-enhancing effects. We found no human fitness trial (WADA, 2026; USADA).
What is the difference between AICAR and MOTS-c?
They are different compounds named in the same WADA entry. AICAR is a small-molecule nucleoside; MOTS-c is a peptide. See what the research shows on MOTS-c (WADA, 2026).
Are there AICAR clinical trials recruiting?
We found none. ClinicalTrials.gov lists 5 records that name acadesine or AICAR as an intervention, and all are completed or terminated (search, November 16, 2026).
Sources
- Višnjić D, et al. AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cells. 2021;10(5):1095. PubMed 34064363
- Dixon R, et al. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol. 1991;31(4):342-7. PubMed 2037706
- Dixon R, et al. Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. J Clin Pharmacol. 1993;33(10):955-8. PubMed 8227467
- Leung JM, et al. An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group. Anesth Analg. 1994;78(3):420-34. PubMed 7818622
- Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Anesthesiology. 1995;83(4):658-73. PubMed 7574044
- Menasché P, et al. Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. J Thorac Cardiovasc Surg. 1995;110(4 Pt 1):1096-106. PubMed 7475138
- Mangano DT, et al. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA. 1997;277(4):325-32. PubMed 9002496
- Mangano DT, et al. Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol. 2006;48(1):206-14. PubMed 16814669
- Newman MF, et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA. 2012;308(2):157-64. PubMed 22782417
- Holdright DR, et al. Effect of acadesine, a new metabolic agent, on exercise-induced myocardial ischemia in chronic stable angina. Cardiovasc Drugs Ther. 1994;8(2):193-7. PubMed 7918131
- de Jonge R, et al. Effect of acadesine on myocardial ischaemia in patients with coronary artery disease. Eur J Pharmacol. 1997;337(1):41-4. PubMed 9389379
- Cuthbertson DJ, et al. 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes. 2007;56(8):2078-84. PubMed 17513706
- Babraj JA, et al. Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status. Am J Physiol Endocrinol Metab. 2009;296(5):E1042-8. PubMed 19190259
- Bosselaar M, et al. Intra-arterial AICA-riboside administration induces NO-dependent vasodilation in vivo in human skeletal muscle. Am J Physiol Endocrinol Metab. 2009;297(3):E759-66. PubMed 19602584
- Bosselaar M, et al. Intravenous AICAR during hyperinsulinemia induces systemic hemodynamic changes but has no local metabolic effect. J Clin Pharmacol. 2011;51(10):1449-58. PubMed 21148051
- Boon H, et al. Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia. 2008;51(10):1893-900. PubMed 18709353
- Van Den Neste E, et al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study. Cancer Chemother Pharmacol. 2013;71(3):581-91. PubMed 23228986
- Cluzeau T, et al. Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia. Int J Mol Sci. 2019;21(1):164. PubMed 31881723
- Narkar VA, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405-15. PubMed 18674809
- Wilcox SH, et al. Chronic treatment of old mice with AICAR reverses age-related changes in exercise performance and skeletal muscle gene expression. FASEB Bioadv. 2025;7(3):e1491. PubMed 40060947
- Brockhoff M, et al. Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I. J Clin Invest. 2017;127(2):549-563. PubMed 28067669
- Cerveró C, et al. Chronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy. Neurotherapeutics. 2016;13(1):198-216. PubMed 26582176
- Bolster DR, et al. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem. 2002;277(27):23977-80. PubMed 11997383
- Halseth AE, et al. Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochem Biophys Res Commun. 2002;294(4):798-805. PubMed 12061777
- Blanco CL, et al. Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, Papio sp. PLoS One. 2018;13(12):e0208757. PubMed 30540820
- Quinn JM, et al. Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J. 2010;24(1):275-85. PubMed 19723702
- Calder MD, et al. Treatment with AICAR inhibits blastocyst development, trophectoderm differentiation and tight junction formation and function in mice. Mol Hum Reprod. 2017;23(11):771-785. PubMed 28962017
- Bowdridge EC, et al. In vitro progesterone production by luteinized human mural granulosa cells is modulated by activation of AMPK and cause of infertility. Reprod Biol Endocrinol. 2017;15(1):76. PubMed 28938894
- Guigas B, et al. AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Biochem J. 2007;404(3):499-507. PubMed 17324122
- Piccolo D, et al. Investigation of ABCA4 Missense Variants and Potential Small Molecule Rescue in Retinal Organoids. Invest Ophthalmol Vis Sci. 2025;66(9):58. PubMed 40693713
- Thevis M, et al. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test Anal. 2011;3(5):331-6. PubMed 21538997
- ClinicalTrials.gov. The five records that name acadesine, AICAR or AICA riboside as an intervention (NCT00004314, NCT00168519, NCT00559624, NCT00872001 with posted results, NCT01813838), November 16, 2026. Search
- U.S. Anti-Doping Agency. What athletes should know about AICAR and others. USADA page
- World Anti-Doping Agency. AICAR: determination of AICAR-ribotide in red blood cells as a long-term marker for an illicit AICAR application (project approved 2011). WADA project page
- World Anti-Doping Agency. 2026 Prohibited List, section S4.4.1 (AMPK activators, including BAM15, AICAR and MOTS-c). WADA document
- U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for acadesine, AICAR and AICA riboside found no application, November 16, 2026. openFDA
- U.S. Food and Drug Administration. openFDA drug listings (NDC): searches for acadesine and AICAR found no listing, November 16, 2026. openFDA NDC
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding (content current as of April 22, 2026; AICAR and acadesine not named). FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (AICAR and acadesine not named). FDA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- National Library of Medicine. PubChem: acadesine (CID 17513) and AICA ribotide (CID 65110). PubChem
- U.S. Food and Drug Administration. Global Substance Registration System: Acadesine (UNII 53IEF47846). GSRS
Last reviewed Nov 16, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.